Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of lutikizumab in moderate to severe hidradenitis suppurativa
2024-510730-40-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 45
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Lutikizumab with Placebo (2 arms). Primary endpoint: HiSCR 75 at Week 16. Planned start Dec 2024; status: authorised.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-510730-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510730-40-00.